Lupin launches first PrecisionSphere long-acting injectable in the U.S.
This technology allows for easier injection with smaller needles and more consistent drug concentrations.
Lupin
Lupin announces strategic partnership program to expand reach of its long-acting injectable platform
Lupin's partnership program is designed to foster collaborations with companies looking to extend their product lifecycles.
Lupin to build $250 million manufacturing facility in Florida
The facility will produce vital respiratory medicines and bolster the company’s role as a global respiratory leader.
Lupin launches ipratropium bromide nasal solution
Ipratropium bromide nasal solution (Nasal Spray), 0.03% and 0.06% are bioequivalent to Atrovent Nasal Spray, 0.03% and 0.06%, of Boehringer Ingelheim Pharmaceuticals.